{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.03","upperLimit":"9.79","value":"8.2"},{"comment":"Due to insufficient number of participants with events, the upper limit of the survival curve hasn't reached 50%, there is no estimate for the upper confidence limit on the median.","groupId":"OG001","lowerLimit":"11.73","upperLimit":"NA","value":"21.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"description":"To evaluate the efficacy of JS001 plus chemotherapy compared with placebo plus chemotherapy as measured by IRC-assessed progression free survival (PFS) according to RECIST v1.1 in all patients.\n\nThe definition of Progressive Disease: At least a 20% increasein the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. or the appearance of one or more new lesions is also considered progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebos: placebo combine with chemotherapy","id":"OG000","title":"Placebo Combine With Chemotherapy"},{"description":"TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy","id":"OG001","title":"TORIPALIMAB INJECTION(JS001 )Combine With Chemotherapy"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1","type":"PRIMARY","unitOfMeasure":"months"}